Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 8/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.48 |
| ▸ | NPY4R | P50391 | 7/20 | 0.45 |
| ▸ | NPY1R | P25929 | 5/20 | 0.45 |
| ▸ | NPY2R | P49146 | 5/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31222411 | 0.90 | NPY4R (0.61) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31222383 | 0.90 | NPY4R (0.61) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL1372389 | 0.89 | OPRD1 (0.55) | OPRD1OPRM1OPRK1MMP2 | |
| SCHEMBL27849221 | 0.87 | OPRD1 (0.44) | OPRD1OPRM1OPRK1NPY4RNPY1R | |
| SCHEMBL11682692 | 0.84 | OPRD1 (0.62) | OPRD1OPRM1OPRK1 | |
| SCHEMBL31222364 | 0.83 | FOLH1 (0.48) | OPRD1OPRM1NPY4RNPY1RNPY2R | |
| SCHEMBL27849228 | 0.82 | OPRD1 (0.48) | OPRD1OPRM1OPRK1NPY4RNPY1R | |
| SCHEMBL31222372 | 0.81 | NPY4R (0.64) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31222361 | 0.81 | NPY4R (0.64) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31222375 | 0.80 | NPY4R (0.68) | NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC (CA) | 2016-09-15 | — | — | US | disclosed |
| EP-2794663-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2014-10-29 | — | — | EP | disclosed |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2011-11-24 | — | — | US | disclosed |
| WO-2010063124-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | OPRD1 4036/4885OPRM1 3822/4885OPRK1 3911/4885 |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | OPRD1 4036/4885OPRM1 3822/4885OPRK1 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.